comparemela.com
Home
Live Updates
Drug Adverse Event - Breaking News
Pages:
2
3
4
5
6
7
8
Latest Breaking News On - Drug adverse event - Page 1 : comparemela.com
Patritumab Deruxtecan (HER3-DXd) in EGFR-Mutated NSCLC Following EGFR TKI and Platinum-Based Chemotherapy: HERTHENA-Lung01
Expert oncologist Helena Yu, MD, reviews data from HERTHENA-Lung01 following the IASLC 2023 World Conference on Lung Cancer and considers how patritumab deruxtecan will fit into clinical practice.
Helena yu
Patritumab deruxtecan
Lung cancer
Non small cell lung cancer
Egfr mutation
Egfr lung cancer
Egfr tki
Herthena lung01
Her3 dxd
Clinical trials
Novel therapy
World conference on lung cancer
Wclc 2023
2023 wclc
Efficacy data
Safety data
The Evolving Treatment Landscape of Small Cell Lung Cancer
Closing out their program on small cell lung cancer management, Laurent Greiller, MD, and Christian Grohé, MD, highlight what excites them most about the evolving treatment paradigm.
Christian groh
Laurent greiller
Evolving paradigms
Evolving treatment landscape
Small cell lung
Small cell lung cancer
Limited stage sclc
Extensive stage sclc
Ls sclc
Es sclc
Novel therapy
Combination therapy
Clinical trials
Bispecific therapy
Bispecific antibodies
Adverse events
Clinical Data With Lurbinectedin in Small Cell Lung Cancer
Key opinion leaders share a focused discussion on lurbinectedin and its evolving role in small cell lung cancer following frontline therapy.
Evolving paradigms
Data with lurbinectedin
Small cell lung
Small cell lung cancer
Limited stage sclc
Extensive stage sclc
Ls sclc
Es sclc
Second line therapy
Second line treatment
Imforte trial
Imforte study
Platinum resistant
Platinum sensitive
Maintenance therapy
Adverse events
Advent of PARP Inhibitors in Metastatic CRPC
Moving on to discuss metastatic castration-resistant prostate cancer, panelists highlight the evolving role of PARP inhibition in this setting.
Treatment approaches
Prostate cancer
Metastatic prostate cancer
Castration resistant prostate cancer
Parp inhibitors
Parp inhibition
Tissue biopsy
Liquid biopsy
Somatic testing
Germline testing
Circulating tumor dna
Cell free dna
Adverse events
Drug adverse event
Talapro 2
Arsi therapy
Bispecifics in Multiple Myeloma: Adverse Event Management
Expert perspectives on adverse event management in patients on bispecific therapy for multiply relapsed multiple myeloma.
Evolving treatment paradigm
Multiple myeloma
Recent updates
Adverse event management
Myeloma cancer
Relapsed refractory multiple myeloma
Multiply relapsed
Later line treatment
Later line therapy
Adverse events
Drug adverse event
Cytokine release syndrome
Immune effector cell associated neurotoxicity syndrome
Prophylactic treatment
Asco 2023
Asco annual meeting
vimarsana © 2020. All Rights Reserved.